Now in the second edition, this incisive handbook examines the persuasive evidence that neurohormonal activation causes cardiac remodeling. That evidence includes large-scale clinical trials of neurohormonal blocking agents, such as angiotensin-converting enzyme (ACE) inhibitors and Beta blockers, in heart failure patients.
The handbook gives careful attention to the favorable impact that these agents have on the clinical course of heart failure patients and provides the basis for the use of these drugs for the treatment of heart failure.